Management of Confirmed Newborn-Screened Patients With Pompe Disease Across the Disease Spectrum.

Published

Journal Article

After a Pompe disease diagnosis is confirmed in infants identified through newborn screening (NBS), when and if to start treatment with enzyme replacement therapy (ERT) with alglucosidase alfa must be determined. In classic infantile-onset Pompe disease, ERT should start as soon as possible. Once started, regular, routine follow-up is necessary to monitor for treatment effects, disease progression, and adverse effects. Decision-making for when or if to start ERT in late-onset Pompe disease (LOPD) is more challenging because patients typically have no measurable signs or symptoms or predictable time of symptom onset at NBS. With LOPD, adequate, ongoing follow-up and assessments for onset or progression of signs and symptoms are important to track disease state and monitor and adjust care before and after treatment is started. Because numerous tests are used to monitor patients at variable frequencies, a standardized approach across centers is lacking. Significant variability in patient assessments may result in missed opportunities for early intervention. Management of Pompe disease requires a comprehensive, multidisciplinary approach with timely disease-specific interventions that target the underlying disease process and symptom-specific manifestations. Regardless of how identified, all patients who have signs or symptoms of the disease require coordinated medical care and follow-up tailored to individual needs throughout their lives. The Pompe Disease Newborn Screening Working Group identifies key considerations before starting and during ERT; summarizes what comprises an indication to start ERT; and provides guidance on how to determine appropriate patient management and monitoring and guide the frequency and type of follow-up assessments for all patients identified through NBS.

Full Text

Duke Authors

Cited Authors

  • Kronn, DF; Day-Salvatore, D; Hwu, W-L; Jones, SA; Nakamura, K; Okuyama, T; Swoboda, KJ; Kishnani, PS; Pompe Disease Newborn Screening Working Group,

Published Date

  • July 2017

Published In

Volume / Issue

  • 140 / Suppl 1

Start / End Page

  • S24 - S45

PubMed ID

  • 29162675

Pubmed Central ID

  • 29162675

Electronic International Standard Serial Number (EISSN)

  • 1098-4275

Digital Object Identifier (DOI)

  • 10.1542/peds.2016-0280E

Language

  • eng

Conference Location

  • United States